FDA Commissioner Robert Califf’s Thursday testimony sparked new conversations about the future of cannabis in the U.S. particularly concerning its medical and recreational classifications. In a recent note, senior analyst Pablo Zuanic from Zuanic & Associates highlights the critical points from Califf’s appearance before the House Committee on Oversight and Accountability. Califf’s assertion that “there is no reason for the DEA to delay” the rescheduling of cannabis grabbed headlines, yet Zuanic urges stakeholders to look deeper into the nuances of Califf’s statements, particularly his insight…
